Masimo (NASDAQ: MASI) has introduced Sleep Halo™, an advanced sleep analysis feature for the Masimo W1® Sport wearable. Sleep Halo uses 70,000+ daily measurements of continuous pulse oximetry data and advanced AI to provide detailed insights into sleep quality, including duration, sleep stages, and desaturation episodes. Users can view these insights and a Sleep Halo score on the Masimo Health app. This technology will also be featured in future Masimo wearables, such as the Masimo Freedom™ Watch and Band. Masimo W1 Sport owners can update their firmware and app to access Sleep Halo.
Positive
- Introduction of Sleep Halo™ enhances the Masimo W1® Sport wearable’s capabilities.
- Sleep Halo™ provides over 70,000 daily measurements for detailed sleep analysis.
- Advanced AI and continuous pulse oximetry offer accurate sleep insights.
- Sleep Halo™ will be included in upcoming Masimo wearables like the Masimo Freedom™ Watch and Band.
- Masimo W1® Sport is available for purchase, enhancing consumer choice in accurate health tracking devices.
The introduction of Sleep Halo for the Masimo W1 wearable is a notable advancement in the wearable tech space. Continuous pulse oximetry and machine learning integration to deliver sleep analysis is an innovative move, leveraging Masimo’s established accuracy in health metrics. The Sleep Halo score could offer more precise and actionable insights compared to other consumer wearables that depend on intermittent data. This feature sets the Masimo W1 apart from competitors and could appeal to health-conscious consumers looking for reliable and comprehensive sleep data.
From a retail investor’s perspective, understanding the technological advancements behind Masimo W1 is crucial. The combination of continuous SpO2 monitoring and advanced AI differentiates this product in a crowded market. Moreover, integrating these features seamlessly into a wearable device that can be updated via firmware suggests strong post-purchase value and consumer retention potential. However, investors should also consider the potential market reception and adoption rates, as the success of such innovative features hinges heavily on consumer trust and validation.
Masimo’s use of scientifically validated sleep metrics derived from EEG benchmarking is an impressive stride in the realm of consumer health wearables. The fact that Sleep Halo has been rigorously tested against reference measurements, including EEG data, underscores its potential reliability and accuracy. This kind of validation is essential for gaining consumer trust, particularly given the backdrop of skepticism about the accuracy of similar devices on the market.
For investors, the clinical validation of Sleep Halo’s sleep stages could mean a competitive edge, especially if Masimo can effectively communicate these benefits to potential users. There’s also the added advantage of leveraging the existing trust in Masimo SET technology, already present in top hospitals. However, it’s important to remain cautious about any possible regulatory hurdles or the necessity for further independent validations to substantiate the claims fully.
The launch of Sleep Halo for the Masimo W1 could place Masimo in a strong position within the wearable technology market, which has seen significant growth in recent years. The focus on sleep health, combined with the advanced tracking capabilities, caters to a burgeoning market of health-conscious consumers who seek accurate and actionable wellness data. Given that other consumer wearables often rely on less precise methods, Masimo’s differentiator can be a significant selling point.
Investors should consider the broader market potential and the competitive landscape. With sleep health becoming a growing concern, especially amid increasing awareness of its importance to overall well-being, Masimo’s accurate and detailed sleep tracking could capture a substantial market share. However, the success will depend on effective marketing strategies and consumer education to highlight these benefits over competing products that might seem more affordable or user-friendly but less accurate.
Sleep Halo Sleep Metrics Are Based on Masimo W1’s Continuous Pulse Oximetry Measurements and Advanced Halo AI Technology
Masimo (NASDAQ: MASI), today announced that the Masimo W1® Sport advanced health tracking wearable is gaining a powerful new feature: scientifically based sleep analysis with Sleep Halo™. Sleep Halo offers overnight sleep data tracking with an unmatched 70,000+ daily measurements of second-by-second continuous health data.
Masimo W1® with Sleep Halo™ (Graphic: Business Wire)
Sleep Halo uses continuous Masimo pulse oximetry and machine learning to provide meaningful insights into the quality of an individual’s sleep, including overall timing, duration of sleep stages, periods of rest and wakefulness, episodes of desaturation, and more. The nightly analysis, including a Sleep Halo score – an algorithmic calculation representing your overall sleep quality – is visualized on the companion Masimo Health smartphone app. The Sleep Halo score and sleep analysis will be featured in all future Masimo wearables, including the upcoming Masimo Freedom™ Watch and Band.
Joe Kiani, Founder and CEO of Masimo, said, “We’re truly excited to launch Sleep Halo for Masimo W1 Sport. For 35 years, Masimo has been dedicated to using breakthrough engineering to help improve lives. Masimo W1 is unique among wearables in being able to continuously measure the wearer’s SpO2 and PR – and that gives us an opportunity to provide a truly informed, robust analysis of how one sleeps. As always, we are committed to providing scientifically backed measurements, which are based on our unmatched, accurate technology, not ‘tarot card logic’ novelties. We benchmarked Sleep Halo with EEG to confirm its stages of sleep are comparable to sleep analysis. We hope that with this new scientifically based Sleep Halo, our customers can improve their sleep hygiene, which has been shown to improve life.”
Today’s consumers are limited to choosing from among a variety of consumer wearables, which use intermittent and often inaccurate data, heavily reliant on movement – which cannot provide reliable or actionable sleep metrics. Masimo W1 – which has been shown to be significantly more accurate than the leading consumer wearable1 – is designed to provide sophisticated and insightful sleep analysis using technology based on Masimo SET®, the primary pulse oximetry technology at all top 10 U.S. hospitals as ranked in the 2024 Newsweek World’s Best Hospitals listing.2 Rigorously tested against reference laboratory measurements, including EEG data, Sleep Halo makes it possible to bring reliable, insightful sleep analysis to everyday people around the world, on a nightly basis, via a lightweight, comfortable wearable, from the convenience of their own home.
Existing Masimo W1 Sport owners will soon be able to update their watch firmware and Masimo Health app to begin their sleep tracking journey. Masimo W1 is available for purchase at www.Masimo.com.
Also available is Masimo W1 Medical, the first and only FDA-cleared watch to provide continuous, real-time SpO2 and PR with an indicator when measurements are outside of their normal ranges.
Masimo W1 Sport and Sleep Halo are for general health and wellness purposes.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.3 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,4 improve CCHD screening in newborns,5 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.6-9 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,10 and is the primary pulse oximetry at all 10 top
RPVi has not received FDA 510(k) clearance and is not available for sale in
References
- Masimo internal whitepaper on file.
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo W1® and Sleep Halo™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Masimo W1 and Sleep Halo, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to the assumption that Sleep Halo will be available on future Masimo wearables including Freedom™ Watch and Band; risks related to COVID-19; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
View source version on businesswire.com:
Media:
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com
Source: Masimo
FAQ
What is Masimo Sleep Halo™?
Sleep Halo™ is an advanced sleep analysis feature for the Masimo W1® Sport wearable, providing detailed insights into sleep quality using continuous pulse oximetry and AI.
How does Masimo Sleep Halo™ work?
Sleep Halo™ uses 70,000+ daily measurements of continuous pulse oximetry data and AI to analyze sleep quality, including duration, sleep stages, and desaturation episodes.
Can current Masimo W1® Sport owners use Sleep Halo™?
Yes, existing Masimo W1® Sport owners can update their watch firmware and Masimo Health app to access Sleep Halo™.
Will Sleep Halo™ be available in other Masimo wearables?
Yes, Sleep Halo™ will be featured in future Masimo wearables, such as the Masimo Freedom™ Watch and Band.
Where can I purchase the Masimo W1® Sport?
The Masimo W1® Sport is available for purchase at www.Masimo.com.
